One year after launching, the trial continues to assess potential treatments and is now expanding internationally. Hear the inside story from trial leaders, clinicians and a patient involved in the study.

Professor Jeremy Day from our OUCRU unit in Ho Chi Minh City, Vietnam, tells us about his research on better treatments for HIV-patients suffering from brain fungal infections

Professor Eduard Sanders from our KWTRP unit in Kilifi, Kenya, tells us about his research on HIV prevention and care

Paul Turner from our COMRU unit in Cambodia tells us about the pressing need for quality laboratory data in low and middle income countries, for better antimicrobial resistance surveillance

Rogier van Doorn from our OUCRU unit in Hanoi, Vietnam, tells us about AMR surveillance data, from antibiotic susceptibility testing results to treatment regimen

James Lee from ERGO/ISARIC in Oxford tells us about the MERMAIDS-ARI project, observational studies for acute respiratory infection (ARI) in adults, a European collaboration of 8 countries with patients recruited from primary and secondary care

Ambrose Agweyu KWTRP in Nairobi tells us about implementation research to improve guidelines, care and outcomes for childhood pneumonia in Kenya

Louise Sigfrid from ISARIC in Oxford tells us about ISARIC epidemic clinical research preparedness and COVID-19 response

Le Van Tan from OUCRU tells us about the natural history and transmission potential of asymptomatic SARS-CoV-2 infection in Ho Chi Minh City, Vietnam. Results of the clinical study are available on medRxiv

ERGO Researcher Conall Watson describes the epidemiological design and development of “Ebola ça Suffit”, the ring vaccination efficacy trial deployed in Guinea during the West African epidemic.

Ifedayo Adetifa from our KWTRP unit in Kilifi, Kenya, speaks about Vaccine impact studies and implications for vaccine policy: case studies from Kenya.

Chris Paton from Oxford Global Health & Care Systems at the University of Oxford speaks about open science approach to artificial intelligence in healthcare

Professor Joel Tarning (MORU) presents highlights on population PK/PD modelling to assess the dosing of antimalarial drugs in vulnerable groups.